This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-17. Anything still debated is marked as such rather than presented as settled.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentadecapeptide | Fifteen amino acids; sequence matches a fragment of a gastric juice protein |
| Molecular formula | C62H98N16O22 | Corresponds to a molecular mass near 1419 Da |
| Primary origin | Fragment of human gastric juice protein BPC | First characterized in the early 1990s |
| Common synonyms | BPC 157; PL 14736; pentadecapeptide BPC 157 | Naming conventions vary across publications |
| Reported stability | Stable in gastric juice during in vitro incubation | Based on laboratory incubation, not clinical data |
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
=== Pharmacokinetics === RO5263397 has shown favorable pharmacokinetic properties for in vivo use based on its physicochemical properties and preclinical research. It is mainly metabolized by N-glucuronidation in humans. UGT2B10 polymorphisms can result in profoundly altered exposure to RO5263397 in humans. Implicated polymorphisms appear to be especially prevalent in people of African descent.
Etoetonitazene is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene. It is an analogue of etonitazene where the ethoxy sidechain has been extended to ethoxyethoxy. It is less potent than other benzimidazole class opioids, but is still a potent mu opioid receptor agonist with around 50x the potency of morphine, and has been sold as a designer drug since around 2022.
On July 23, 2013, Taco Bell announced they were discontinuing the sale of kids' meals and accompanying toys at all of their U.S.–based restaurants by January 2014. Some outlets ceased their sale as early as July 2013. On August 6, 2013, the chain announced it was expanding its test market of "Waffle Tacos" to ≈100 restaurants in Fresno, California, Omaha, Nebraska, and Chattanooga, Tennessee, beginning on August 8 of that year. The Waffle Taco included scrambled eggs, sausage, and a side of syrup. It was the top–selling item during breakfast hours at the five Southern California restaurants where they had been test–released earlier in 2013. The breakfast menu started on March 27, 2014. Other items include: the A.M. Crunchwrap, Cinnabon Delights, Breakfast Burrito, A.M. Grilled Sausage Flatbread Melt, Hash Browns, Coffee and Orange Juice. The ad–campaign, which began March 27, used twenty-five men who were named Ronald McDonald, a reference to the famous clown mascot of McDonald's. Another commercial advertisement for the Waffle Taco features the narrator singing, "I've been eating Egg McMuffins since 1984. But when I saw Taco Bell made a Waffle Taco, I figured I would get with the times" set to the tune of "Old MacDonald Had a Farm"— another shot at McDonald's. On April 28, 2014, Taco Bell ridiculed McDonald's for its "out–dated muffins", in a breakfast campaign devised by Taylor. The advertisement stated the claim that the McMuffin belonged in 1984. In October 2014, Taco Bell launched the Pink Strawberry Starburst Freeze beverage for a limited time.
== Pharmacology == Sunobinop has nanomolar affinity (Ki) and efficacy (EC50) at human recombinant nociceptin/orphanin-FQ peptide (NOP) receptors. It has a high degree of functional selectivity for the NOP receptor. Sunobinop is a low affinity antagonist at human mu and kappa opioid receptors, and is a low affinity weak partial agonist at human delta opioid receptors.
=== Schizophrenia === It has been proposed that schizophrenia may be due to an increase or a decrease in glutamate signaling, leading to abnormal excitatory signaling in the prefrontal cortex region of the brain. Glutamate release by astrocytes has been linked to the synchrony of neurons in the hippocampus and cortex. A decrease in system Xc- activity may result in an increase in synaptic glutamate and a decrease in extrasynaptic glutamate. Administration of N-acetylcysteine leads to an increase in extrasynaptic NMDA receptor activation, suggesting that glutamate released from system Xc- may cause the activation of extrasynaptic NMDA receptors. A decrease in system Xc- activity may cause a decrease in the activation of extrasynaptic NMDA receptors due to either a decrease in extrasynaptic Glutamate levels or a decrease in glutathione levels after the decrease in cystine transport. On the other hand, a decrease in system Xc- activity may lead to an increase in the activation of synaptic NMDA receptors due to the decrease in activation of Group 2 mGluRs. A decrease in nonvesicular release of glutamate leads to an increase in expression of postsynaptic glutamate receptors, such as NMDA receptors. A disruption in nonvesicular glutamate release may affect synapse formation, lead to altered release of neurotransmitters, and could even disturb cortical migration during development. All of these seem to be associated with schizophrenia.
Sources: en.wikipedia.org
=== Death of Charles === Charles had been in poor health for some time. After going shopping on a chilly day in Funchal to buy toys for Carl Ludwig, he was struck by an attack of bronchitis. This rapidly worsened into pneumonia, not helped by the inadequate medical care available. Several of the children and staff were also ill, and Zita (at the time eight months pregnant) helped nurse them all. Charles weakened and died on 1 April, his last words to his wife being "I love you so much." Charles was 34 years old. After his funeral, a witness said of Zita "This woman really is to be admired. She did not, for one second, lose her composure... she greeted the people on all sides and then spoke to those who had helped out with the funeral. They were all under her charm." Zita wore mourning black in Charles's memory throughout 67 years of widowhood.
=== Cinematography === Ricoh GR digital cameras, a series of digital cameras manufactured by Ricoh Ricoh GR (large sensor compact camera), the current line of cameras in the GR series Golmaal Returns, a Hindi comedy film Generator Rex, an animated sci-fi series Guilty Remnant, a fictional cult in The Leftovers (TV series)
==== Total synthesis ==== The first structure elucidation and total synthesis of the cocaine molecule was accomplished by Richard Willstätter in 1898. Willstätter's synthesis involved constructing the cocaine structure from simpler precursors, notably via the intermediate tropinone. Subsequent significant contributions to understanding the synthetic pathway and stereochemistry were made by Robert Robinson and Edward Leete. Cocaine contains four chiral centers (1R, 2R, 3S, and 5S), two of which are configurationally dependent, resulting in eight possible stereoisomers. The formation of inactive stereoisomers, along with various synthetic by-products, limits both the yield and purity of the final product. Although the chemical synthesis of cocaine is technically feasible, it remains impractical due to its high cost, low efficiency, and complex stereoselective synthesis compared to extraction from natural plant sources. While domestic clandestine laboratories could theoretically reduce reliance on offshore production and international smuggling—as seen with illicit methamphetamine—manufacture and synthetic production of cocaine remains rare. Large-scale commercial synthesis has not been explored.
== Uses == The plant is native to the Caribbean, where the Taíno people were the first recorded peoples to use it and cultivate it. In 1560, Jean Nicot de Villemain, then French ambassador to Portugal, brought tobacco seeds and leaves as a "wonder drug" to the French court. In 1586 the botanist Jaques Dalechamps gave the plant the name of Herba nicotiana, which was also adopted by Linné. It was considered a decorative plant at first, then a panacea, before it became a common snuff and tobacco plant. Tobacco arrived in Africa at the beginning of the 17th century. The leaf extract was a popular pest control method up to the beginning of the 20th century. In 1851, the Belgian chemist Jean Stas documented the use of tobacco extract as a murder poison. The Belgian count Hippolyte Visart de Bocarmé had poisoned his brother-in-law with tobacco leaf extract in order to acquire some urgently needed money. This was the first exact proof of alkaloids in forensic medicine. It is now commercially cultivated worldwide. All parts of the plant contain nicotine, which can be extracted and used as an insecticide. The dried leaves can also be used; they remain effective for 6 months after drying. The juice of the leaves can be rubbed on the body as an insect repellent. The leaves can be dried and chewed as an intoxicant. The dried leaves are also used as snuff or are smoked. This is the main species that is used to make cigarettes, cigars, and other products. A drying oil is obtained from the seed. Other varieties are cultivated as ornamental plants.
=== Pharmacodynamics === Romergoline shows high affinity for the dopamine D2 receptor (Ki = 6.5 nM), α2-adrenergic receptor (Ki = 4.0 nM), and serotonin 5-HT1A receptor (Ki = 4.0 nM). It also possesses moderate (submicromolar) affinity for the dopamine D1 receptor (Ki = 55 nM) and ketanserin-labeled serotonin 5-HT2 receptor (Ki = 24 nM). Conversely, the drug shows slight or negligible affinity for the α1-adrenergic receptor (Ki = 113 nM), muscarinic acetylcholine receptors (Ki = >10,000 nM), and sigma receptors (Ki = >10,000 nM). Romergoline is said to act as both a dopamine receptor agonist and antagonist, depending on the circumstances. More specifically, the drug is said to act as a D2 receptor silent antagonist under normal dopamine-replete circumstances, but in a dopamine-depleted state, it acts as a powerful dopamine D1 receptor full agonist. This transformation of the drug's activity is thought to be due to development of dopamine D1 receptor supersensitivity with dopamine depletion. Romergoline produces hypolocomotion in rodents and monkeys, inhibits apomorphine-induced climbing behavior in rodents, causes antiemetic effects in dogs, strongly increases prolactin levels in rodents, and antagonizes amphetamine-induced toxicity in rodents. With dopamine depletion however, romergoline induces hyperlocomotion and contralateral turning behavior in 6-hydroxydopamine-lesioned rodents, reverses MPTP-induced akinesia and parkinsonism in monkeys, and reverses reserpine-induced hypokinesia.
Sources: en.wikipedia.org
It is a synthetic peptide of fifteen amino acids whose sequence matches a fragment of a protein found in human gastric juice. It is studied mainly in laboratory and animal research rather than as an approved medicine.
The letters abbreviate body protection compound, the name given to the parent protein isolated from gastric juice. The number is an identifier attached to the specific fragment, not a dose or a description of a chemical property.
The sequence corresponds to a segment of an endogenous gastric protein, but the isolated fifteen-amino-acid peptide is a synthetic construct. Whether the free fragment circulates in humans at measurable levels is not clearly established in the published literature.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.